SCHEMBL3528616

SCHEMBL3528616

CCOC(=O)C1CN(Cc2ccccc2)c2nc(SC)ncc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.41
CACNA2D1 P54289 1/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 7/20 0.40
POLB P06746 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
MAPT P10636 5/20 0.38
HPGD P15428 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 2/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
USP30 Q70CQ3 1/20 0.38
LMNA P02545 1/20 0.37
RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11101244 0.87 KMT2A (0.46) MEN1KMT2AALDH1A1POLBTDP1
SCHEMBL3291782 0.85 ALDH1A1 (0.44) SLC6A2CACNA2D1MEN1KMT2AALDH1A1
SCHEMBL537550 0.83 MEN1 (0.38) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL9956454 0.82 MEN1 (0.47) SLC6A2CACNA2D1MEN1KMT2AALDH1A1
SCHEMBL537471 0.80 MEN1 (0.36) SLC6A2CACNA2D1MEN1KMT2AALDH1A1
SCHEMBL3534676 0.78 KMT2A (0.45) MEN1KMT2AALDH1A1POLBTDP1
SCHEMBL3291780 0.77 MEN1 (0.44) MEN1KMT2AALDH1A1POLBTDP1
SCHEMBL1832087 0.76 ALDH1A1 (0.57) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL538740 0.75 CACNA1G (0.38) MEN1KMT2AALDH1A1HPGDTSHR
SCHEMBL11585055 0.74 ALDH1A1 (0.43) MEN1KMT2AALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642270-B2 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-05 US disclosed
EP-1937681-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP disclosed
WO-2007033232-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR SLC6A2 4078/4885CACNA2D1 2633/4885MEN1 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.